• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

    2/4/22 5:00:06 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email
    SC 13G 1 d9172057_13-g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

    Plus Therapeutics Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    72941H400
    (CUSIP Number)

     

     

    January 28, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 72941H400    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Parkman Healthcare Partners LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         

    1,508,508

     
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         

    1,508,508

     
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         

    1,508,508

     
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, IA

     

     

     
     

     

     

     

    CUSIP No 72941H400  

     

         
    1. NAME OF REPORTING PERSONS  
         
      Parkman Healthcare Partners Holdings LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         

    1,508,508

     
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         

    1,508,508

     
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
     

    1,508,508

     
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     

     

     
     

     

     

     

    CUSIP No 72941H400  

     

         
    1. NAME OF REPORTING PERSONS  
         
      Parkman Healthcare Partners Holdings GP LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       

    (a) [_]

       

    (b) [X]

         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
     

    1,508,508

     
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         

    1,508,508

     
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         

    1,508,508

     
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
       

    [_]

         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     
     

     

     

     

    CUSIP No 72941H400    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Gregory Martinez  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         

    1,508,508

     
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         

    1,508,508

     
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
     

    1,508,508

     
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      7.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN

     

     

     
     

     

     

    CUSIP No 72941H400    

     

    Item 1. (a). Name of Issuer:  
           
        Plus Therapeutics, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    4200 Marathon Boulevard, Suite 200

    Austin, Texas 78756

    United States of America

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Parkman Healthcare Partners LLC

    Parkman Healthcare Partners Holdings LP

    Parkman Healthcare Partners Holdings GP LLC

    Gregory Martinez 

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Parkman Healthcare Partners LLC

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

    Parkman Healthcare Partners Holdings LP

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

    Parkman Healthcare Partners Holdings GP LLC

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

    Gregory Martinez

    c/o Parkman Healthcare Partners LLC

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A. 

     

     

      (c). Citizenship:  
           
       

    Parkman Healthcare Partners LLC – Delaware limited liability company

    Parkman Healthcare Partners Holdings LP – Delaware limited partnership

    Parkman Healthcare Partners Holdings GP LLC – Delaware limited liability company

    Gregory Martinez– United States citizen

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  

     

      (e). CUSIP Number:  
           
        72941H400  

     

     
     

     

     

    Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    1,508,508 shares deemed beneficially owned by Parkman Healthcare Partners LLC

    1,508,508 shares deemed beneficially owned by Parkman Healthcare Partners Holdings LP

    1,508,508 shares deemed beneficially owned by Parkman Healthcare Partners Holdings GP LLC

    1,508,508 shares deemed beneficially owned by Gregory Martinez

     

      (b)   Percent of class:
         
       

    7.4% deemed beneficially owned by Parkman Healthcare Partners LLC

    7.4% deemed beneficially owned by Parkman Healthcare Partners Holdings LP

    7.4% deemed beneficially owned by Parkman Healthcare Partners Holdings GP LLC

    7.4% deemed beneficially owned by Gregory Martinez

     

      (c)   Number of shares as to which Parkman Healthcare Partners LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,508,508 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,508,508 .

     

      Number of shares as to which Parkman Healthcare Partners Holdings LP has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,508,508 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,508,508 .

     

      Number of shares as to which Parkman Healthcare Partners Holdings GP LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,508,508 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,508,508 .
     

     

    Number of shares as to which Gregory Martinez has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 1,508,508 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 1,508,508 .

     

     
     

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

      N/A  
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

    The shares of the Issuer reported herein are owned by advisory clients or funds managed by Parkman Healthcare Partners LLC and/or its related persons’ accounts.

       
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

      Parkman Healthcare Partners LLC *
       
       
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
      Title: Managing Member
         
         
         
      PARKMAN HEALTHCARE PARTNERS HOLDINGS LP*
       
         
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
      Title: Managing Member
         
         
      PARKMAN HEALTHCARE PARTNERS HOLDINGS GP LLC*
       
         
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
      Title: Managing Member
         
         
       
      GREGORY MARTINEZ*
         
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
         
         
    February 4, 2022    
         

     

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated February 4, 2022 relating to the Common Stock, par value $0.001 per share of Plus Therapeutics, Inc., shall be filed on behalf of the undersigned.

      Parkman Healthcare Partners LLC
       
       
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
      Title: Managing Member
         
         
         
      PARKMAN HEALTHCARE PARTNERS HOLDINGS LP
       
         
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
      Title: Managing Member
         
         
      PARKMAN HEALTHCARE PARTNERS HOLDINGS GP LLC
       
         
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
      Title: Managing Member
         
         
       
      GREGORY MARTINEZ
         
      By: /s/ Gregory Martinez
      Name: Gregory Martinez
         
         
    February 4, 2022    
         

     

     

    Get the next $PSTV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

      D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

      3/17/25 7:41:57 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright initiated coverage on Plus Therapeutics

      HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy

      2/11/21 7:44:56 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00

      2/11/21 6:52:36 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

      The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company's CNSide Cerebrospinal Fluid (CSF) Assay Platform for patients at risk for central nervous system metastases HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide") will be sh

      7/10/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

      HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the treatment of its initial patients in the Company's ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM). The dose optimization trial builds on promising results from the Company's completed Phase 1 single-dose escalation study, which demonstrated the feasibility of REYOBIQ for treating LM. The trial is designed in alignment with the FDA's Project

      7/8/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

      Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from the Cancer Prevention & Research Institute of Texas HOUSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the initiation of the ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM). The dose optimi

      6/30/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/17/24 7:00:04 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/16/24 7:00:03 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/13/24 6:04:12 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

      SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      6/5/24 7:26:01 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/13/23 3:25:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/11/22 7:53:23 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Financials

    Live finance-specific insights

    See more
    • Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

      U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide"). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients s

      6/26/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

      HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call  Date/Time:Thursday, June 26, 2025 @ 9:00 AM ET Webcast: https://edge.media-server.com/mmc/p/97egitn8 Dial-in Link: https://register-conf.media-server.com/re

      6/25/25 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The rece

      3/27/25 4:05:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    SEC Filings

    See more
    • SEC Form PRE 14A filed by PLUS THERAPEUTICS Inc.

      PRE 14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      7/11/25 4:06:44 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by PLUS THERAPEUTICS Inc.

      EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/24/25 12:15:25 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form RW filed by PLUS THERAPEUTICS Inc.

      RW - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/23/25 4:15:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clowes Howard

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:10 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Hawkins Richard J

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Petersen Greg

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

      HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

      4/23/25 8:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

      AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

      2/20/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

      Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a

      6/7/24 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care